Complete Guide to Vixarelimab Pharmacokinetics
Overview
Vixarelimab is a Monoclonal antibody used in the Dermatology / Chronic pruritic disorders therapeutic area. It is indicated for Prurigo nodularis and chronic pruritic conditions. Interactive vixarelimab PK simulator based on a 2-compartment TMDD/QSS population pharmacokinetic model reported by Tang et al. 2026 in healthy volunteers and patients with chronic pruritic conditions.
Mechanism of Action
Vixarelimab exerts its pharmacological effect by targeting OSMRβ. As a Monoclonal antibody, it modulates this target to achieve therapeutic efficacy in Prurigo nodularis and chronic pruritic conditions. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This 2-compartment TMDD PopPK model for Vixarelimab characterizes the time-course of drug concentrations following SC and IV administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Vixarelimab is administered via the SC and IV route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Dermatology / Chronic pruritic disorders therapeutic area, for the treatment of Prurigo nodularis and chronic pruritic conditions, understanding the pharmacokinetics of Vixarelimab is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Vixarelimab pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive Vixarelimab PK Simulator
Explore Vixarelimab pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Vixarelimab?
The elimination half-life of Vixarelimab depends on patient-specific factors. Use our interactive Vixarelimab PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Vixarelimab administered?
Vixarelimab is administered via the SC and IV route. It is indicated for Prurigo nodularis and chronic pruritic conditions. As a Monoclonal antibody, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Vixarelimab?
Key pharmacokinetic parameters for Vixarelimab include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a 2-compartment TMDD PopPK model to characterize the pharmacokinetics of Vixarelimab.
Can I simulate Vixarelimab dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Vixarelimab PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.